The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the TEAM pathology study.
John M. S. Bartlett
No relevant relationships to disclose
Kenneth J. Bloom
Employment or Leadership Position - Clarient
Tammy Robson
No relevant relationships to disclose
Thomas J. Lawton
Consultant or Advisory Role - Clarient
Cornelis J. H. Van De Velde
No relevant relationships to disclose
Douglas T. Ross
Employment or Leadership Position - Clarient
Research Funding - Clarient
Robert S. Seitz
Employment or Leadership Position - Clarient
Rodney A. Beck
Employment or Leadership Position - Clarient
Research Funding - Clarient
Annette Hasenburg
No relevant relationships to disclose
Dirk Guenter Kieback
No relevant relationships to disclose
Hein Putter
No relevant relationships to disclose
Christos Markopoulos
No relevant relationships to disclose
Luc Yves Dirix
No relevant relationships to disclose
Caroline M. Seynaeve
No relevant relationships to disclose
Daniel Rea
No relevant relationships to disclose